Evidence map›Paper›PMID 29535134›Full record

ArticleCancer discovery2018

Organoids May Point to Best Therapy.

Registry-linked trialAbstract readNewsComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05189171 (MicroOrganoSphere Drug Screen to Lead Care), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05189171 completednot on this mapstarted 2022, after this paper: background citation

MicroOrganoSphere Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)

TypeobservationalSponsorXilis, Inc.Ran2022 to 2024Enrolled46ConditionsColorectal NeoplasmsArmsMicroOrganoSphere (MOS) drug screen
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Organoid technology and applications in cancer research.Journal of hematology & oncology · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a recent study, organoids derived from the metastatic tumors of patients with gastrointestinal cancers had a similar response to treatment as the original tumors. Eventually, organoids could become a useful tool for identifying the most effective therapy for each patient.

Indexed as

Gastrointestinal NeoplasmsOrganoidsHumansPrecision Medicine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.